Web Exclusives

High tumor immune cell levels may identify women with HER2+ breast cancer who may benefit from chemotherapy alone

Women with HER2-positive breast cancer who had higher levels of immune cells in their tumors showed a lower risk of cancer recurrence after treatment with chemotherapy alone.

Adding pictilisib to fulvestrant may benefit advanced ER/PR+ breast cancer

In women with aromatase inhibitor-resistant, advanced or metastatic breast cancer positive for both estrogen receptor (ER) and progesterone receptor (PR), adding pictilisib (previously GDC-0941) to the endocrine therapeutic fulvestrant increased survival.

Adding ovarian suppression to tamoxifen reduced recurrence for some premenopausal breast cancer

Among premenopausal women with early stage, HR-positive breast cancer, the addition of ovarian suppression to tamoxifen reduced breast cancer recurrence.

Tamoxifen found to lower breast cancer rates among high-risk women in trial

The International Breast Cancer Intervention Study-I (IBIS-I) trial found that tamoxifen significantly decreased the incidence of all breast cancers, according to data presented at the 2014 San Antonio Breast Cancer Symposium.

Pembrolizumab safe, and even effective in some patients, for triple-negative breast cancer

Pembrolizumab was well tolerated and yielded durable responses in patients with metastatic triple-negative breast cancer, according to recent trial data.

Capecitabine does not improve survival in elderly patients with early stage breast cancer

In elderly patients with moderate- to high-risk early stage breast cancer for whom standard chemotherapy is too toxic, capecitabine did not improve outcomes when tested as monotherapy, according to recent data.

Rociletinib produces response in treatment-resistant advanced non-small cell lung cancer (NSCLC)

A new drug that targets common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), and a type of the mutation responsible for treatment resistance, has shown promising results in a phase I/II clinical trial.

Drug combination produces good response rates in advanced papillary renal cell carcinoma (pRCC)

Patients with advanced papillary renal cell carcinoma (pRCC) have shown good response to a combination of two existing anticancer drugs, according to recent research.

IDH1 mutation inhibitor first to demonstrate anticancer activity

The first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1 has shown clinical activity in patients with advanced acute myeloid leukemia (AML) with the IDH1 mutation.

Wide variation exists in the quality and content of clinical cancer guidelines

A review of top clinical guidelines for rectal cancer shows a variety of treatment recommendations.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs